Last reviewed · How we verify
Plavix® and PA32540 — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
Plavix® and PA32540 (Plavix® and PA32540) — POZEN.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Plavix® and PA32540 TARGET | Plavix® and PA32540 | POZEN | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Plavix® and PA32540 CI watch — RSS
- Plavix® and PA32540 CI watch — Atom
- Plavix® and PA32540 CI watch — JSON
- Plavix® and PA32540 alone — RSS
Cite this brief
Drug Landscape (2026). Plavix® and PA32540 — Competitive Intelligence Brief. https://druglandscape.com/ci/plavix-and-pa32540. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab